Zetagen Therapeutics Raises USD9.79M in Series B Funding
Summary
The company intends to use the funds to support the progression of its R&D efforts of additional oncological pipeline assets as well as ancillary osteologic treatments. In addition to ZetaMet™, the funding will be used for the development of ZetaMAST™ for the treatment of metastatic lesions to soft tissue organs, as well as other oncologic and osteologic pipeline assets. Led by Joe C. Loy, CEO, Zetagen Therapeutics is a clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic cancers to bone and other organs as well as osteologic interventions. The company was recently issued IP directly associated with the development of ZetaMAST™, which is a formulation designed for intra-tumoral injection in soft tissue organs like the liver, lung and or brain. Its pipeline encompasses further oncological solutions, targeting metastatic prostate cancer and addressing Skeletal Related Events (SREs), such as Z-Pros™ and ZetaMet Flowable™, alongside supplementary treatments for osteological conditions like ZetaFuse™ and ZetaBase®.